NIH Launches COVID-19 Blood-Clotting Treatment Trials

Sept. 12, 2020

The National Institutes of Health announced last week that it has launched Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.  
 
Collectively known as ACTIV-4 Antithrombotics, the trials will provide critical insights that could help guide the care of patients with COVID-19, particularly those who suffer from life-threatening blood clots. Trial planning and development work is being done through a collaborative effort with a number of universities, including the University of Illinois at Chicago.